Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1988 1
1989 2
1990 7
1991 3
1992 5
1993 3
1994 4
1995 4
1996 8
1997 8
1998 7
1999 5
2000 3
2001 2
2002 5
2003 5
2004 4
2005 6
2006 7
2007 6
2008 4
2009 5
2010 7
2011 8
2012 15
2013 12
2014 12
2015 20
2016 6
2017 9
2018 11
2019 22
2020 30
2021 14
2022 15
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

275 results

Results by year

Filters applied: . Clear all
Page 1
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes.
Kidman J, Zemek RM, Sidhom JW, Correa D, Principe N, Sheikh F, Fear VS, Forbes CA, Chopra A, Boon L, Zaitouny A, de Jong E, Holt RA, Jones M, Millward MJ, Lassmann T, Forrest ARR, Nowak AK, Watson M, Lake RA, Lesterhuis WJ, Chee J. Kidman J, et al. Among authors: millward mj. Oncoimmunology. 2024 Apr 26;13(1):2345859. doi: 10.1080/2162402X.2024.2345859. eCollection 2024. Oncoimmunology. 2024. PMID: 38686178 Free PMC article.
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy.
Abed A, Beasley AB, Reid AL, Law N, Calapre L, Millward M, Lo J, Gray ES. Abed A, et al. Among authors: millward m. ESMO Open. 2023 Dec;8(6):102066. doi: 10.1016/j.esmoop.2023.102066. Epub 2023 Nov 22. ESMO Open. 2023. PMID: 37995426 Free PMC article.
The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study.
Davidson AL, Dressel U, Norris S, Canson DM, Glubb DM, Fortuno C, Hollway GE, Parsons MT, Vidgen ME, Holmes O, Koufariotis LT, Lakis V, Leonard C, Wood S, Xu Q, McCart Reed AE, Pickett HA, Al-Shinnag MK, Austin RL, Burke J, Cops EJ, Nichols CB, Goodwin A, Harris MT, Higgins MJ, Ip EL, Kiraly-Borri C, Lau C, Mansour JL, Millward MW, Monnik MJ, Pachter NS, Ragunathan A, Susman RD, Townshend SL, Trainer AH, Troth SL, Tucker KM, Wallis MJ, Walsh M, Williams RA, Winship IM, Newell F, Tudini E, Pearson JV, Poplawski NK, Mar Fan HG, James PA, Spurdle AB, Waddell N, Ward RL. Davidson AL, et al. Among authors: millward mw. Genome Med. 2023 Sep 19;15(1):74. doi: 10.1186/s13073-023-01223-1. Genome Med. 2023. PMID: 37723522 Free PMC article.
Detection of metastases using circulating tumour DNA in uveal melanoma.
Beasley AB, de Bruyn DP, Calapre L, Al-Ogaili Z, Isaacs TW, Bentel J, Reid AL, Dwarkasing RS, Pereira MR, Khattak MA, Meniawy TM, Millward M, Brosens E, de Klein A, Chen FK, Kiliҫ E, Gray ES. Beasley AB, et al. Among authors: millward m. J Cancer Res Clin Oncol. 2023 Nov;149(16):14953-14963. doi: 10.1007/s00432-023-05271-3. Epub 2023 Aug 22. J Cancer Res Clin Oncol. 2023. PMID: 37608028 Free PMC article.
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Cass SH, Tobin JWD, Seo YD, Gener-Ricos G, Keung EZ, Burton EM, Davies MA, McQuade JL, Lazar AJ, Mason R, Millward M, Sandhu S, Khoo C, Warburton L, Guerra V, Haydon A, Dearden H, Menzies AM, Carlino MS, Smith JL, Mollee P, Burgess M, Mapp S, Keane C, Atkinson V, Parikh SA, Markovic SN, Ding W, Call TG, Hampel PJ, Long GV, Wargo JA, Ferrajoli A. Cass SH, et al. Among authors: millward m. Ann Oncol. 2023 Sep;34(9):796-805. doi: 10.1016/j.annonc.2023.06.007. Epub 2023 Jul 4. Ann Oncol. 2023. PMID: 37414216
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J, Del Vecchio M, Mandalá M, Gogas H, Arance Fernandez AM, Dalle S, Cowey CL, Schenker M, Grob JJ, Chiarion-Sileni V, Marquez-Rodas I, Butler MO, Di Giacomo AM, Middleton MR, Lutzky J, de la Cruz-Merino L, Arenberger P, Atkinson V, Hill AG, Fecher LA, Millward M, Nathan PD, Khushalani NI, Queirolo P, Ritchings C, Lobo M, Askelson M, Tang H, Dolfi S, Ascierto PA, Weber J. Larkin J, et al. Among authors: millward m. Clin Cancer Res. 2023 Sep 1;29(17):3352-3361. doi: 10.1158/1078-0432.CCR-22-3145. Clin Cancer Res. 2023. PMID: 37058595 Free PMC article.
275 results